Evangeli Bista Joins the PATH Expert Group as an Independent Expert: Bringing the Patient Perspective into the New Era of AI in Cancer Care

A new contribution to the European dialogue on safe, responsible and human-centred Artificial Intelligence in healthcare

Evangeli Bista, Co-founder and Head of Operations and Development of Kapa3 – Cancer Guidance Centre, has been invited to join the Expert Group of the European research and innovation project PATH – Patient AI Treatment Hub as an independent expert.

Her participation is undertaken in a personal and independent capacity, with her professional affiliation to Kapa3 – Cancer Guidance Centre, creating an opportunity to bring into the European dialogue experience gained through direct engagement with people affected by cancer, survivors, caregivers and healthcare professionals. The PATH Terms explicitly define Expert Group members as acting independently rather than as partners, employees, agents or subcontractors of the Consortium.

What is PATH – Patient AI Treatment Hub?

PATH – Patient AI Treatment Hub is a European research and innovation project focused on supporting the safe and effective integration of Artificial Intelligence into cancer care through the development of a secure, interoperable and privacy-preserving digital platform.

The project aims to explore how Artificial Intelligence tools can be safely integrated into cancer-care pathways, supporting healthcare professionals and contributing to more personalised approaches while safeguarding privacy and health data.

At the heart of this effort lies a critical question:

How can technological innovation create meaningful value for patients while preserving trust, human oversight, safety and equity?

Participation in the PATH Expert Group

As a member of the PATH Expert Group, Evangeli Bista will contribute independent expertise, opinions, input, comments and feedback in relation to selected project use cases and activities.

The experience developed through Kapa3’s work can contribute to discussions around issues such as:

  • patient-centred cancer care,
  • patient navigation across health and social-care systems,
  • equitable access to information and services,
  • health and digital literacy,
  • health and social rights,
  • responsible use and protection of health data,
  • transparency and human oversight in Artificial Intelligence systems,
  • meaningful involvement of patients and civil society in technology design,
  • and translating technological innovation into real value for people.

Why the Patient Voice Must Be Part of Innovation

Artificial Intelligence is creating new possibilities for healthcare and cancer care. At the same time, its growing use raises important questions concerning trust, transparency, safety, equitable access and human oversight.

For Kapa3, the development of a digital solution cannot begin solely with the question of what is technologically possible.

It must also ask:

What does the patient actually need?

Can people understand the information they receive?

Do they know where that information comes from?

Can they trust the system?

Is it clear when Artificial Intelligence is being used and when human professional judgement is required?

Could digital inequalities lead to new inequalities in healthcare?

And ultimately, does innovation genuinely improve the experience and pathway of a person facing cancer?

These are questions that we believe should remain at the centre of the European discussion on Artificial Intelligence in healthcare.

Kapa3’s experience in digital health

Evangeli Bista’s participation in the PATH Expert Group comes at a time when Kapa3 is systematically expanding its work in digital health, patient navigation and the responsible use of emerging technologies to support people affected by cancer.

This broader work also includes MYRTO – Digital Navigator for Health and Social Rights, an independent Kapa3 initiative developed to help transform complex and often fragmented information on rights, benefits and administrative procedures into more accessible, structured and evidence-based guidance for patients and caregivers.

MYRTO is not part of PATH, and the two initiatives are independent from one another.

However, the experience of developing patient-facing digital services has reinforced several principles that Kapa3 considers essential:

reliable information, transparent sources, understandable communication, data protection, human oversight and a clear pathway to professional support when technology alone is not enough.

This distinction is also important from an intellectual-property perspective, since the PATH Terms preserve intellectual property that exists independently of the Expert’s Services and is not incorporated into PATH Contributions.

From information to trust

Digital transformation in healthcare is not simply about more data, more algorithms or more applications.

It is about creating greater understanding, better access and stronger trust.

For a person facing cancer, information has value when it can be translated into a meaningful next step.

Technology has value when it reduces — rather than increases — complexity.

And Artificial Intelligence has value when it strengthens, rather than replaces, human care, professional judgement and the patient’s ability to participate meaningfully in decisions affecting their life and health.

A new opportunity to contribute to the European dialogue

For Kapa3, the invitation to Evangeli Bista to participate as an independent expert in the PATH Expert Group represents an important opportunity to bring into the European dialogue experience, needs and concerns emerging from the real-world context of cancer care and patient support.

The objective remains clear:

Artificial Intelligence in healthcare should advance with safety, transparency, responsibility, equitable access and meaningful involvement of the people it is designed to serve.

Because innovation creates real value when it is designed with people and for people.


PATH – Patient AI Treatment Hub | At a glance

Field: Artificial Intelligence and data in cancer care
Project: PATH – Patient AI Treatment Hub
Focus: Safe and effective integration of AI into cancer care through secure, interoperable and privacy-preserving approaches.
Expert Group: Independent external experts providing expertise, opinions, input, comments and feedback to the Project.
Independent Expert: Evangeli Bista
Professional role: Co-founder & Head of Operations and Development
Affiliation: Kapa3 – Cancer Guidance Centre

 

The Active Role of Patient Organizations in Shaping Public Policy: How Our Health Advocacy Ef orts Are Put into Action

At the Cancer Patient Guidance Center, we believe that the voices of patients, their families, and the organizations that represent them must be heard loud and clear where decisions are made.

Improving the quality of life for cancer patients, ensuring access to new treatments, and meeting the needs of caregivers are not just requests but rights that are asserted through organized advocacy. To make this a reality, the right tools are needed.

The new “Guide to Mapping Public Consultation Tools”

As part of the “ENERGO – Toward an Open State” project, HIGGS has created a practical guide that maps the available mechanisms for participation at the local, national, and European levels.

This guide serves as a roadmap for Civil Society Organizations (CSOs), providing a detailed overview of:
• How institutional consultation tools function
• The opportunities for organizations to actively participate in policy-making
• The requirements for accessing these mechanisms
• The challenges and limitations, so that our interventions are well-informed and effective

Why might this be of interest to the beneficiaries of our Center?

Participation in shaping public policy is not an abstract concept. In cancer care, it translates into very specific changes:
1. Equal access to care: advocating for better infrastructure, shorter wait times, and free access to innovative medications.
2. Support for caregivers: establishing leave policies, benefits, and support systems for the people who stand by their side
3. Rights in the workplace: protecting cancer patients from discrimination in the workplace during and after treatment.

Summary & Structure of the Public Consultation Tools Guide

The “Public Consultation Tools Guide” was developed as part of the project “ENERGO – Toward an Open State” (implemented by HIGGS and co-funded by the European Union, the Bodossaki Foundation, and the NGO Support Centre). It is a practical reference tool designed to empower civil society organizations (CSOs) by strengthening their capacity for meaningful, evidence-based participation in public policy-making and strategic advocacy.

The guide is organized into the following sections:

1. Introduction & Institutional Landscape: This section presents the framework for the guide’s development, which was based on research and experiential tools involving dozens of civil society organizations. It analyzes the challenges of the institutional landscape, noting that the main obstacle for organizations is not the absence of tools, but rather the fragmentation, lack of visibility, and complexity of existing mechanisms,

2. National Tools for Public Consultation & Participation: maps and presents in detail the tools available in Greece, such as OpenGov, the KEDE & LocalWatch consultation platform, Vouliwatch, the YPEN Participation Platform, the National Register of Procedures (“Mitos”), Open Council & Crowd Participation, as well as Diafania & POTHEN.

3. European Public Consultation & Participation Tools: presents mechanisms for engagement at the European Union level, such as Have Your Say, the European Citizens’ Initiative (ECI), Consul Democracy, Loomio & Decidim, and others.

4. Tool Selection Guide & Conclusions: Provides consistent evaluation criteria (purpose, implementing body, prerequisites, limitations) so that each organization can select the most appropriate tool based on the objective of its engagement.

About the “ENERGO” Project & the PLATO Program

The “ENERGO: Toward an Open State – Participation, Advocacy, and Empowerment of Civil
Society Organizations” project is being implemented as part of the PLATO program, with HIGGS serving as the implementing partner. The PLATO program (“Protecting democracy, human rights, and the rule of law through an open civic space”) aims to strengthen the fundamental rights and values of the EU in both Greece and Cyprus. It is co-funded by the European Union through the Citizens, Equality, Rights and Values (CERV) program, the Bodossaki Foundation, and the NGO Support Center. The Bodossaki
Foundation serves as the coordinator in partnership with the NGO Support Center.

View and download the guiderZT9sW-Οδηγός Εργαλείων Δημόσιας Διαβούλευσης.

 

Artificial Intelligence (AI) is transforming the fight against cancer.The European Cancer Organisation’s “Harnessing AI for Cancer Care in Europe” report

Artificial Intelligence (AI) is transforming the fight against cancer, enabling machines to learn, reason, and assist humans in detecting, diagnosing and treating the disease more accurately and efficiently. It works by analysing vast amounts of data, learning patterns, and making predictions or recommendations to support human decision-making.

Cancer care is rapidly transforming with the use of AI, which serves as a powerful tool in prevention, detection, treatment and research of the disease. The European Cancer Organisation’s “Harnessing AI for Cancer Care in Europe” report states that AI has the potential to transform every stage of the cancer pathway. Simultaneously, the report emphasises the need for AI to be used responsibly, by protecting patients, upholding ethical standards, and aligning with European values, to ensure its benefits are delivered fairly and effectively across healthcare systems.

The Promise of AI in Cancer Care

The report highlights several ways AI can improve cancer outcomes across the care pathway. In primary prevention, AI can analyse genetic, environmental, and lifestyle data to identify high-risk patients and guide preventive strategies before symptoms appear. For early detection, AI can dramatically speed up screening, reducing test interpretation from days to hours, improving accuracy, and lowering missed diagnoses. In diagnostics, deep-learning models trained on large datasets can detect even the smallest lesions, prioritise urgent cases, and support more precise diagnoses. AI also enables personalised treatment by integrating tumour genomics, imaging data, and real-world outcomes to help clinicians select the most effective therapies for individual patients. Finally, in drug development, AI can identify promising compounds and targets, shortening traditional development cycles and discovering new uses for existing medicines.

Challenges That Cannot Be Ignored

However, the report also highlights significant risks associated with AI in cancer care. Key concerns include regulatory gaps as AI tools advance faster than current rules, making it challenging to ensure they remain safe, accurate, and accountable. Many promising AI systems require further validation in real-world clinical settings, as untested tools could lead to misdiagnoses or unsafe decisions. Bias and inequity are also risks, since AI trained on unrepresentative data may produce less accurate recommendations for specific patient groups. Implementation barriers, such as limited infrastructure, funding, and trained staff, can hinder the integration of AI into everyday healthcare. Finally, trust issues may arise, as both patients and clinicians need to understand and have confidence in AI systems for them to be effectively adopted.

Policy Recommendations: A Roadmap for Safe and Effective Use

To tackle these challenges, the report puts forward four key recommendations. First, it calls for national standards and validation frameworks, including speciality-specific rules and post-market monitoring of AI tools. Second, it emphasises the importance of training and literacy, proposing pan-European AI education to ensure that at least 50% of oncology professionals are confident in using AI by 2030. Third, the report urges robust regulatory guidance and oversight, including EU-wide support for data protection under GDPR, implementation of the AI Act, and strong patient engagement to ensure clinical accountability. Finally, it highlights the need for investment in data infrastructure, leveraging the European Health Data Space to harmonise systems, modernise cancer registries, and build representative datasets that support safe and effective AI deployment.

Why This Matters for Kapa3

Building on these advancements, K3 is preparing to launch its digital assistant, “Myrto”, in 2026. Designed to harness the power of AI, “Myrto” will support patients and healthcare professionals across the cancer care pathway. By integrating cutting-edge AI capabilities with user-friendly guidance, “Myrto” exemplifies K3’s commitment to improving outcomes, streamlining workflows, and empowering both patients and clinicians in Europe’s rapidly evolving healthcare landscape.

To see the full article, please click here.

https://www.europeancancer.org/resources/publications/harnessing-ai-for-cancer-care-in-europe.html

Digital poverty and social exclusion

Internet of Things in EU Households: Who is Connecting and How

A recent Eurostat article looks at how individuals across the European Union are using internet-connected devices (IoT).

In 2024, 70% of EU citizens aged 16–74 reported using Internet of Things (IoT) devices—smart technologies such as internet-connected TVs, smart speakers, fitness trackers, or doorbells. While internet-connected TVs were the most widely used device (58%), wearables like smartwatches or fitness trackers were used by 30%, and home audio systems by 19%. Less common were smart home appliances, energy management systems, security devices, health-related IoT devices, and toys.

Usage patterns vary across age groups. The youngest adults (16–24) show the highest adoption of entertainment-related IoT devices, while the 35–44 age group uses more home-related devices.

Country differences are significant: the Netherlands leads with 95% of citizens using IoT devices, while Greece ranks fourth from the last, just above Romania, Bulgaria, and Poland.

The trend towards digital inequality is concerning. Special attention is needed from social justice actors to avoid automation-driven discrimination facilitated by artificial intelligence. While digitalisation can enhance the efficiency of social protection, there is a risk it may instead serve austerity measures.

Read more here